Pinsent Masons Advises Accord Healthcare in Exclusive Licence Agreement with Myovant Sciences to Commercialise ORGOVYX® for Advanced Hormone-Sensitive Prostate Cancer in Europe
14 Jun 2022 | 03:35 pm |
Pinsent Masons represented Accord Healthcare Ltd in an exclusive license agreement with Myovant Sciences to commercialise relugolix, Myovant’s advanced hormone-sensitive prostate cancer treatment, under the trade name ORGOVYX® in the European Economic Area, United Kingdom, Switzerland and Turkey.
Under the terms of the agreement, Myovant will receive an upfront payment of US$50 million, and is eligible to receive milestones which could total up to a further US$90.5 million. Myovant will continue to lead the global development of relugolix and provide initial product supply to Accord. Accord will be responsible for certain local clinical development, all commercialization for its territories, and has the option to manufacture relugolix in the future.
The Pinsent Masons transactions team was led by Life Sciences Transactions partner Gina Bicknell, with primary support from solicitor Kiah York and legal director Mario Subramaniam.
Key Contacts
Latest press releases
Show me all press releasesPinsent Masons advises PIC on £132m buy-in of Tomkins 2008 pension scheme retirement benefits plan
Pinsent Masons advises PIC on £132m buy-in of Tomkins 2008 pension scheme retirement benefits plan.
Pinsent Masons advises on Umicore’s € 591 million sustainability linked note fundraising
Multinational law firm Pinsent Masons has advised various institutional investors in relation to Umicore’s € 591 million sustainability linked note fundraising.
Pinsent Masons advises Alveo on its sale to Symphony Technology Group
Pinsent Masons has advised the shareholders of Alveo, including funds managed by Sovereign Capital Partners (SCP), on its sale to Symphony Technology Group (STG).
People who viewed this press release also viewed
Show me all press releasesPinsent Masons advises UMS Consulting on its acquisition by Expleo
Multinational law firm Pinsent Masons has advised the shareholders of UMS Consulting GmbH & Co. KG on the sale of their shares to Expleo Group S.A.S.
Pinsent Masons launches parallel trade monitoring platform for life sciences sector
Multinational law firm Pinsent Masons launches innovative online tool to help life sciences organisations grappling with parallel trade management.
Pinsent Masons appoints third life sciences partner in Amsterdam
A year after launching its presence in The Netherlands, multinational law firm Pinsent Masons has appointed its fifth partner in Amsterdam, welcoming life sciences patent specialist Judith Krens.
For all media enquiries, including arranging an interview with one of our spokespeople, please contact the press office on
Location contacts
Europe: [email protected]
Asia: [email protected]
Middle East: [email protected]
Australia: [email protected]